Literature DB >> 29390932

Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop.

Daryl Tan1,2, Jae Hoon Lee3, Wenming Chen4, Kazuyuki Shimizu5, Jian Hou6, Kenshi Suzuki7, Weerasak Nawarawong8, Shang-Yi Huang9, Chor Sang Chim10, Kihyun Kim11, Lalit Kumar12, Pankaj Malhotra13, Wee Joo Chng14,15, Brian Durie16.   

Abstract

Predicated on our improved understanding of the disease biology, we have seen remarkable advances in the management of multiple myeloma over the past few years. Recently approved drugs have radically transformed the treatment paradigm and improved survivals of myeloma patients. The progress has necessitated revision of the diagnostic criteria, risk-stratification and response definition. The huge disparities in economy, healthcare infrastructure and access to novel drugs among different Asian countries will hinder the delivery of optimum myeloma care to patients managed in resource-constrained environments. In the light of the tremendous recent changes and evolution in myeloma management, it is timely that the resource-stratified guidelines from the Asian Myeloma Network be revised to provide updated recommendations for Asia physicians practicing under various healthcare reimbursement systems. This review will highlight the most recent advances and our recommendations on how they could be integrated in both resource-abundant and resource-constrained facilities.

Entities:  

Keywords:  Myeloma; novel agents; resource-stratified

Mesh:

Substances:

Year:  2018        PMID: 29390932     DOI: 10.1080/10428194.2018.1427858

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Stem Cell Transplantation in Multiple Myeloma: Very Much Alive and Kicking.

Authors:  Uday Yanamandra; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2019-03-13       Impact factor: 0.900

2.  Myeloma at Cross Roads in India.

Authors:  Uday Yanamandra; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-08       Impact factor: 0.900

Review 3.  Risk Stratification in Multiple Myeloma in Indian Settings.

Authors:  Rajan Kapoor; Rajiv Kumar; A P Dubey
Journal:  Indian J Hematol Blood Transfus       Date:  2019-12-14       Impact factor: 0.900

Review 4.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

Review 5.  Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective.

Authors:  Ahmad Ibrahim; Nabil Chamseddine; Jean El-Cheikh; Colette Hanna; Walid Moukadem; Fady Nasr; Ahmad Younis; Ali Bazarbachi
Journal:  Clin Hematol Int       Date:  2022-08-30

6.  Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Shinsuke Iida; Shang-Yi Huang; Naoki Takezako; Wee Joo Chng; Anita Zahlten-Kumeli; Martina A Sersch; Julia Li; Mei Huang; Jae Hoon Lee
Journal:  Int J Hematol       Date:  2019-08-06       Impact factor: 2.490

7.  Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.

Authors:  Naoki Takezako; Hirohiko Shibayama; Hiroshi Handa; Shotaro Hagiwara; Shuji Ozaki; Kenshi Suzuki; Hiroshi Kosugi; Masaki Ri; Isamu Sugiura; Ilseung Choi; Toshihiro Miyamoto; Shinsuke Iida
Journal:  Int J Hematol       Date:  2020-10-10       Impact factor: 2.490

8.  Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China.

Authors:  Zhongqing Zou; Tingting Guo; Jian Cui; Wenjiao Tang; Yan Li; Fangfang Wang; Tian Dong; Yunfan Yang; Yan Feng; Matthew Ho; Li Zhang; Ling Pan; Ting Niu
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

9.  Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.

Authors:  Tomoaki Fujisaki; Takayuki Ishikawa; Hiroyuki Takamatsu; Kenshi Suzuki; Chang-Ki Min; Jae Hoon Lee; Jianping Wang; Robin Carson; Wendy Crist; Ming Qi; Koji Nagafuji
Journal:  Ann Hematol       Date:  2019-10-16       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.